Prostate Cancer
Improving the diagnosis of early prostate cancer.
EDx700TM / PSA Test Combination
Combining EDx700™ with the Prostate Specific Antigen (PSA) test is being developed to provide greater clinical certainty for assessing the presence of prostate cancer and its clinical risk.
Prostate cancer is the most common cancer in men with close to $12 billion spent annually on the treatment of prostate cancer. Approximately 16.4 million PSA tests were conducted in 2015 in the United States alone1. The PSA test alone has a false positive rate of about 75%2 – in 100 men who have an elevated PSA level, only 25 of them will actually have prostate cancer.
We are developing EDx700™ as a confirmatory test to be used in conjunction with the PSA test in order to significantly lower the rate of false positive and false negative results that are associated with using the PSA test alone, and thereby reduce the need for unnecessary invasive prostate biopsies.
Footnotes:
1 Journal of the National Cancer Institute
2 American Cancer Society (assuming a cutoff level of 4 ng/ml)